Results 171 to 180 of about 39,021 (326)

587P Short lead time and high rates of concomitant radiographic recurrences for ctDNA-based minimal residual disease assays colorectal cancer (CRC) during surveillance: Results from the MD Anderson INTERCEPT program [PDF]

, 2023
Madhulika Eluri, N.A. Dasari, G. Maddalena, Andrew F. Bent, Andrew J. Pellatt, Ashwathy Balachandran Pillai, Kristin Alfaro-Munoz, Robert J. Kell, Timothy E. Newhook, Abhineet Uppal, Tsuyoshi Konishi, Van K. Morris, Scott Kopetz   +12 more
openalex   +1 more source

Fast enrichment and detection of circulating tumor cells from large volumes of whole blood of breast cancer patients utilizing a functionalized bioaffinity CTC filtration membrane

International Journal of Cancer, Volume 158, Issue 6, Page 1713-1725, 15 March 2026.
What's new? Circulating tumor cells (CTCs) are promising prognostic biomarkers for cancer. CTCs are sometimes very sparse; however, they present technical challenges for their enrichment from whole blood. Here, the authors tested the CTC enrichment capacity of a new nickel‐based filtration membrane and compared its efficacy to that of an FDA‐approved ...
Leonie F. Ott, Laura Keller, Nathan Bentley, Hümeyra Husseini‐Wüsthoff, René Werner, Marc Zinggeler, Jakoba Heidler, Parinaz Mossahebi Mohammadi, Cornelia Coith, Anne Pradines, Nikolas H. Stoecklein, Malte Löptien, Sven Peine, Maria Geffken, Corinna Güsmer, Mina Netkova‐Heintzen, Volkmar Müller, Elena Laakmann, Verena Thewes, Thomas M. Deutsch, Laura L. Michel, Andreas Schneeweiss, Andreas Trumpp, Jürgen Rühe, Thomas Brandtstetter, Sabine Riethdorf, Klaus Pantel   +26 more
wiley   +1 more source

Local Anesthetics in Cancer: Mechanisms and Translational Perspectives

MedComm – Oncology, Volume 5, Issue 1, March 2026.
Local anesthetics demonstrate multifaceted antitumor effects that collectively contribute to cancer suppression. Beyond canonical sodium channel blockade, these agents exert the following pharmacological actions: inhibition of tumor cell proliferation, suppression of migration and invasion, induction of proapoptotic pathways, attenuation of ...
Wan‐li Wang, Tu Huang, Yi‐hang Hao, Min Zheng, Xin‐hua Liang   +4 more
wiley   +1 more source

Multimodal Framework in Lung Cancer Management: Integrating Liquid Biopsy with Traditional Diagnostic Techniques

Cancer Management and Research
Wenlong Qi,1 Lin Tian,2 Jianan Xu,2 Zhenyu Li,2 Tan Wang2 1Changchun University of Traditional Chinese Medicine, Changchun, Jilin, 130000, People’s Republic of China; 2Affiliated Hospital of Changchun University of Traditional Chinese Medicine, Changchun,
Qi W, Tian L, Xu J, Li Z, Wang T
doaj  

CtDNA-guided de-escalation of adjuvant chemotherapy in stage III colon cancer: early model-based evaluation of cost-effectiveness

Therapeutic Advances in Medical Oncology
Background: All stage III colon cancer (CC) patients are recommended adjuvant chemotherapy (ACT) after surgery, while over half are already cured by surgery alone.
Haoyue Wang, Astrid Kramer, Marjolein J. E. Greuter, Carmen Rubio-Alarcón, Birgit Lissenberg-Witte, Gerrit A. Meijer, Niels F. M. Kok, Daan van den Broek, Geraldine R. Vink, Jeanine M. L. Roodhart, Mark Sausen, Remond J. A. Fijneman, Veerle M. H. Coupé   +12 more
doaj   +1 more source

RT‐PCR–Based Detection of Bone Marrow Involvement in Ewing Sarcoma: Diagnostic Validity and Prognostic Relevance

Pediatric Blood &Cancer, Volume 73, Issue 2, February 2026.
ABSTRACT Background In Ewing sarcoma (EwS), metastases, including those to bone marrow (BM), are the main factors influencing prognosis. Although reverse transcription polymerase chain reaction (RT‐PCR) offers greater sensitivity, the current EWING protocol defines BM metastases solely using light microscopic detection.
Thanh Pham, Andreas Ranft, Victor Rechl, Susanne Jabar, Wolfgang Hartmann, Kim Falkenberg, Heribert Jürgens, Norbert Graf, Torsten Keßler, Markus Metzler, Thomas Klingebiel, Thorsten Simon, Martin Benesch, Uta Dirksen   +13 more
wiley   +1 more source

Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer

Nature Communications
No consensus strategies exist for prognosticating metastatic castration-resistant prostate cancer (mCRPC). Circulating tumor DNA fraction (ctDNA%) is increasingly reported by commercial and laboratory tests but its utility for risk stratification is ...
Nicolette M. Fonseca, Corinne Maurice-Dror, Cameron Herberts, Wilson Tu, William Fan, Andrew J. Murtha, Catarina Kollmannsberger, Edmond M. Kwan, Karan Parekh, Elena Schönlau, Cecily Q. Bernales, Gráinne Donnellan, Sarah W. S. Ng, Takayuki Sumiyoshi, Joanna Vergidis, Krista Noonan, Daygen L. Finch, Muhammad Zulfiqar, Stacy Miller, Sunil Parimi, Jean-Michel Lavoie, Edward Hardy, Maryam Soleimani, Lucia Nappi, Bernhard J. Eigl, Christian Kollmannsberger, Sinja Taavitsainen, Matti Nykter, Sofie H. Tolmeijer, Emmy Boerrigter, Niven Mehra, Nielka P. van Erp, Bram De Laere, Johan Lindberg, Henrik Grönberg, Daniel J. Khalaf, Matti Annala, Kim N. Chi, Alexander W. Wyatt   +38 more
doaj   +1 more source

Bispecific Antibodies Versus Chimeric Antigen Receptor T‐Cell Therapy in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma: A Comparative Narrative Review of Efficacy, Safety, and Accessibility

Cancer Medicine, Volume 15, Issue 2, February 2026.
ABSTRACT Introduction Diffuse large B‐cell lymphoma (DLBCL) is the most common subtype of non‐Hodgkin lymphoma, and despite advances in frontline therapies such as rituximab, cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), vincristine sulfate (Oncovin), and prednisone, approximately 30%–40% of patients develop relapsed or refractory (
Dana Sofian Abou, Husna Irfan Thalib, Fayza Akil, Samia Zuhair Sabbagh, Hala Sofian Abou, Mable Pereira, Fatma ElSayed Hassan   +6 more
wiley   +1 more source

1815P Emergent circulating tumor DNA (ctDNA) variants and ctDNA burden dynamics with potential associations with talazoparib antitumor activity in TALAPRO-1 [PDF]

, 2023
Elena Castro, Douglas Laird, T. Dorff, Shuang G. Zhao, Inge M. van Oort, Donatello Gasparro, Fabio Calabrò, Sandro Pignata, Lajos Géczi, Philippe Barthélémy, Deepak Kilari, J.F. Hopkins, Hsiang‐Cheng Chen, Cynthia G. Healy, Jijumon Chelliserry, Giorgio V. Scagliotti, Johann S. de Bono, N. Mehra, Karim Fizazi   +18 more
openalex   +1 more source

Minimal residual disease in solid tumors: Clinical applications and future directions

Cancer, Volume 132, Issue 3, 1 February 2026.
Abstract Minimal residual disease (MRD) refers to the presence of residual cancer cells or tumor‐derived fragments that persist after treatment and remain undetectable by conventional imaging or protein‐based assays. Circulating tumor DNA (ctDNA) has emerged as a dynamic biomarker for MRD detection.
Theresa Abdo, Ahmad Alhalabi, Sacha Yaghi, Mohammad Aloran, You Li, María Herrán, Rami Tfayli, Thomas A. Samuel, Zeina Nahleh   +8 more
wiley   +1 more source